Understanding Variation in Sets of N-of-1 Trials. by Araujo, A. et al.
RESEARCH ARTICLE
Understanding Variation in Sets of N-of-1
Trials
Artur Araujo1, Steven Julious2, Stephen Senn1*
1 Competence Center for Methodology and Statistics, Luxembourg Institute of Health, Strassen,
Luxembourg, 2 Medical Statistics Group, School of Health and Related Research, University of Sheffield,
Sheffield, United Kingdom
* stephen.senn@lih.lu
Abstract
A recent paper in this journal by Chen and Chen has used computer simulations to examine
a number of approaches to analysing sets of n-of-1 trials. We have examined such designs
using a more theoretical approach based on considering the purpose of analysis and the
structure as regards randomisation that the design uses. We show that different purposes
require different analyses and that these in turn may produce quite different results. Our
approach to incorporating the randomisation employed when the purpose is to test a null
hypothesis of strict equality of the treatment makes use of Nelder’s theory of general bal-
ance. However, where the purpose is to make inferences about the effects for individual
patients, we show that a mixed model is needed. There are strong parallels to the difference
between fixed and random effects meta-analyses and these are discussed.
Introduction
N-of-1 trials are studies in which the effects of treatment are studied by following an individual
patient over time with the treatments given being varied (randomised) from period to period.
Thus, different treatments will be tried on different occasions by a given patient according to a
randomisation scheme determined by the ‘trialist’, who may be the patient’s treating physician,
in an attempt to improve treatment for that patient.
N-of-1 trials have a long history that predates the modern term—which was proposed in
the 1980s by an influential group of researchers at McMaster University in Canada, including
Gordon Guyatt and David Sackett[1–3]. It has also been the case, of course, that efficacy has
been accepted as proven on occasion by single or at least very few successful cases. The rabies
vaccine of Pasteur or the early studies of penicillin are cases in point. However, in this article
we shall be concerned with designs in which at least two treatments are compared and where
the treatments are compared within patient by switching the treatment given from occasion to
occasion. We are further interested in the situation where more than one patient is treated.
An early example of n-of-1 trials was provided by Cushny and Peebles[4], who in their
famous study of optical isomerism, gave three possible soporifics on multiple different occa-
sions with intervening control nights to inmates of the "Insane Asylum at Kalamazoo", in
order to examine the effect of treatment on ‘hours of sleep gained’[5]. These data were later
used by Student in his famous t-test paper[6].
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Cushny and Peebles did not use randomisation but this was advocated in 1930 by RA Fisher
in The Design of Experiments[7], albeit not in a medical context, in a famous account of his test-
ing of the ability of Rothamsted algologist Muriel Bristol to distinguish cups of tea by taste
according to the order in which milk had been poured[8].
Perhaps the most important forerunner in the medical field is Paul Martini’s innovative but
at the time neglected monograph of 1932[9, 10]. In this work he stressed the importance of
control, blinding, replication and statistical analysis in determining causation in medicine and
advocated the approach of repeatedly testing individual patients where possible.
A more modern example is provided by the trial of nicotine chewing gum in ulcerative coli-
tis carried out by Lashner et al[11]. Seven subjects were allocated to two two-week periods of
treatment with nicotine and two with placebo. Measurement was limited to the latter part of
each period to minimise the possible effect of carry-over and a number of scales were used to
measure outcome. For a recent review, advocacy and recommendation of the design, we refer
the reader to Duan et al[12].
N-of-1 trials can be encountered under various names. In the social science literature, they
go by the name of single-case or single-subject designs and are quite common. There are, for
example, at least four monographs [13–16] devoted to statistical approaches to analysing such
trials in psychology or sociology. In fact, RA Fisher describes the tea-tasting trial as a ‘psycho-
physical experiment’[7] (p11). However, in this paper we shall restrict our attention to the
medical application of such trials and, in particular, to methods of analysing the results that
use either randomisation theory or mixed models, and in particular meta-analysis, all of which
are a very common approaches in medical statistics.
One of the attractions of n-of-1 trials is that the fact that patients act as their own control
means that results can be obtained using fewer patients. There are two reasons for this. First
the number of observations per patient is increased. Second, a source of variation, the ‘main
effect’ of patients can be eliminated. This means that for rare diseases they can be an attractive
option. Generally, it is necessary that the condition being treated is long-term and that the
effects of treatment are reversible as regards the particular outcome being measured, otherwise
repeated switches of treatment given in order to compare them, is either not a practical possi-
ble or likely to deceive.
A referee has rightly pointed out to us that n-of-1 trials have found wide-spread application
in examining established therapies with a view to personalising their use. We agree and,
indeed, more than 20 years ago one of us wrote an editorial arguing that this was their most
useful application[17]. However, our participation in IDEAL (Integrated DEsign and AnaLysis
of small population group trials) a European Union funded FP7 project on statistical
approaches to studying rare diseases, has led to our evaluating n-of-1 trials as a possible pri-
mary means to investigate the effects of treatment. Both these purposes are reflected in this
paper.
Thus, as discussed above, a reason to undertake n-of-1 trials could be the efficiency in
studying treatments. However, n-of-1 trials are also useful for establishing the personal com-
ponent of response to treatment. A common notion in the medical literature is that this will be
done individually ab initio for each patient. An n-of-1 protocol thus becomes a means of estab-
lishing for a given patient, using only results from that patient, what works best for them.
The information from one patient only might also be useful as the basis for indicating
whether a treatment works at all, the idea being that if it works in at least one patient it may
work in others. This would generally require rather a long series of episodes of treatment and
possibly complex modelling. There has been some work on such series, a key paper is that of
Rochon[18]. The emphasis in this paper is not on analysing individual trials but instead on
approaches to analysing series of n-of-1 trials carried out in a number of patients.
Variation in N-of-1 Trials
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Where we have data on many patients an interesting challenge is to combine results from a
given patient with those from other patients to provide better prediction of effects for the indi-
vidual patient. The basic idea is simply explained in terms of two extremes. First, if we have
lots of information from many previous patients but do not have the possibility of experiment-
ing on the current one but simply have to make a recommendation, then the estimated treat-
ment effect, based on all the results of others, will be what we should use. On the other hand,
given an extremely long ‘n-of-1’ series during which two treatments have been compared in
one patient, the experience of others is of little relevance. In the intermediate case, with a little
information on the current patient, some weighted average of the two extremes (only the
results of others versus only the results of this patient) may perform better. This is what ‘mixed
models’ can produce via so-called ‘shrinkage estimators’[19].
A further use is to establish the existence of treatment-by-patient interaction. A set of n-of-
1 trials permits treatment-by-patient interaction, which is otherwise confounded with other
sources of variation, to be identifiable. Whether such an interaction is substantial or negligible
can be an indication as to what extent it is worth taking up the challenge to find ways of per-
sonalising medicine based on covariate information (for example, genetic markers)[20–22].
In this paper we shall mainly deal with the analysis of n-of-1 trials, although, inevitably,
some matters of design will have to be touched on, since design affects analysis. We restrict
our attention to the situation where a series of n-of-1 trials are performed according to a com-
mon protocol. Important papers discussing the analysis of such cases are those of Zucker and
colleagues[23, 24]. From another point of view, such a series taken together, forms a cross-
over trial [25, 26], albeit one in which the same treatment is given more than once to each
patient. Such designs are sometimes discussed in the literature of cross-over trials but usually
in the context of providing means of estimating carry-over effects rather than individualising
treatment. See the third edition of Jones and Kenward for some illustrations of this[27].
We propose to examine a number of methods including four that were proposed in an
informative paper by Chen and Chen[28] in their investigation of approaches to analysing a
series of n-of-1 trials. To these four methods we shall add a fifth, the summary measures
approach. However, our main contribution will be to provide a framework in which analysis is
linked to design and purpose. We shall add estimation, the production of valid confidence
intervals and shrinkage estimates, to the purpose of hypothesis testing that Chen and Chen
considered. We shall show that these other purposes lead to an alternative perspective on suit-
able techniques. We will also make a comparison to meta-analysis and the framework that we
provide will additionally illuminate a long-standing controversy between the use of fixed effect
and random effects.
Following Chen and Chen[28] we shall restrict our attention to continuous measures.
Although binary and count data can also be important their inclusion in this paper would
make it long. We plan to revisit these data in a further paper. However, we will make some
brief comments on approaches to analysing such data at the end of this paper
The outline of the paper is as follows. In section two we shall present the findings of Chen
and Chen[28] briefly but also introduce one further approach. In section three we shall then
consider carefully a set of n-of-1 trials in terms of their block structure as understood by what
might be termed ‘The Rothamsted School’ of analysis of variance associated with statisticians
such as Fisher[29–31], Yates[32], Nelder[33, 34] and Bailey[35, 36]. This school regards the fol-
lowing as being key to establishing appropriate approaches to testing hypotheses: 1) identifica-
tion of sources of variation in the experimental material 2) identification of ‘blocks’ to control
such variation 3) method of randomisation used.
In the fourth section we shall introduce a model that can be used for simulation and analy-
sis and move beyond hypothesis testing to cover estimation and prediction, both for groups
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PLOS ONE | DOI:10.1371/journal.pone.0167167 December 1, 2016 3 / 24
and individuals, and present some theoretical results and in the fifth we shall confirm and
extend these using simulation. In the sixth section we shall give a simple simulated example to
illustrate approaches to analysis. We shall discuss our findings in the seventh section and in
the eighth present our conclusions and recommendations.
Before proceeding, however, we make two remarks about random effects. The first is a mat-
ter of terminology. Patients vary in their state of health. For example, some have higher blood
pressure than others. If we choose to regard such variation as random in a model, this is an
example of a random main effect. Patients may also vary in their response to treatment. For
example, some might respond better to beta-blockers and others to ACE inhibitors. If we
chose to model such variation in response as random, this is an example of a random interac-
tion. A similar distinction is important in meta-analysis[37], where the fact that the treatment
effect (difference between treatments) may vary (apparently randomly) from trial to trial is an
example of a random treatment-by-trial interaction, whereas the fact that average values may
vary from trial to trial (apparently randomly) is an example of a random main effect of trial.
Clearly the main and interaction effects in trials can have their origins in main and random
effects in patients.
The second point is to do with modelling treatment-by-patient interaction. It could be con-
tended that testing such interactions is not particularly important. We agree. However, esti-
mating the treatment-by-patient interaction is part of the process of fitting a mixed effect
model, even if the fitting of the model happens in one step so, that this aspect is partly hidden.
The connection to meta-analysis is of interest here. When one has sets of n-of-1 trials, since
the set of repeated episodes of treatment for a given patient can be regarded as the ‘trial’.
Indeed, Chen and Chen[28] use meta-analysis as one of their four methods of analysis. How-
ever, meta-analysis, shows the two faces of interaction. Cochran’s Q statistic can be compared
to the degrees of freedom to form a test or can be used, as in the approach of DerSimonian and
Laird[38], to estimate the random effect. The fact that we shall illustrate how treatment-by-
patient interaction may be estimated does not imply that we regard testing such an effect as
being more important than fitting a mixed model. In particular we reject as being completely
inappropriate testing treatment-by-patient interaction as being a means of choosing between
fixed and random effect models. As we shall explain, and as has been explained elsewhere in
connection with meta.analysis[39] the difference between these two models is one of purpose.
The Methods and Recommendations of the Chen and Chen Paper
The paper by Chen and Chen[19] considers designs in which two treatments A and B are com-
pared. They assume n patients will either be treated in three or in four cycles of treatment.
Each cycle consists of two pairs of what we shall call occasions and in each such pair of occa-
sions A is given once and B is given once, the order being randomised. In what follows, we
shall assume a general case in which the number of cycles per patient is k, where Chen and
Chen[28] would either have k = 3 or 4 (we shall assume k is the same for all patients in any
given design and that there are no missing data but will touch briefly on the more general case
where this is not the case). There are thus nk cycles in total.The number of occasions is 2 per
cycle and we shall refer to the product of cycle and occasions as periods. Thus there are 2k peri-
ods of observation per patient and if we refer to the sum total of all periods of observation over
all patients as episodes of treatment we then have 2nk episodes in total.
Chen and Chen compare four approaches to analysis which we consider below along with
an additional fifth approach. These are shown in Table 1.
The key recommendations of Chen and Chen[28] can be summarised thus: if it may be
assumed there is no carry-over effect, the matched t approach (method 1 above) is best.
Variation in N-of-1 Trials
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However, if it is assumed there is a carry-over, use the mixed model approach (method 3
above) on the original observations (although they found that the matched pairs t-test also per-
formed well).
Of course, as in any method of investigation using simulations, the conclusions depend not
only on the model used for analysis but also on the model used for simulation. For example,
the methods that Chen and Chen use for simulating data allow for compound symmetry (with
three possible parameter settings) or an auto-regressive structure (with two parameter settings)
but the error models used do not allow for a random treatment-by-patient interaction How-
ever, two of the four methods of estimation not recommended can allow for such a random
effect, namely methods 2 and 4.
Whether or not a random treatment-by-patient interaction should be allowed for is at least
partly a question of purpose. If the purpose is strict hypothesis-testing, that is to say to establish
whether there is any evidence of difference at all between treatments, then given the proposed
randomisation, as we shall show below, method 1 is an acceptable approach (although it can
be improved on). However, if the objective is to produce improved estimates for future
patients by shrinking these estimates towards the overall mean, then method 1 cannot deliver
this. The issue is very similar to that in meta-analysis with fixed effects approaches being fine
for hypothesis testing but random effects approaches having some advantages for estimation
[39].
A further relevant issue is the method of randomisation employed. Again, as we shall show
below method 2 is not really consistent with the method of randomisation suggested.
In summary, the purpose and approach to randomisation, both of which are related to
assumed structure of the experimental material and hence the models, need to be examined
carefully to decide on the approach to analysis to be undertaken. In the next section we pro-
pose to examine these issues.
Some theoretical considerations
We shall examine the design considered by Chen and Chen[28] in terms of the approach of
The Rothamsted School, which is implemented in the algorithms that the statistical package
Table 1. Methods for analysis n-of-1 trials.
Approach Description
Method 1 A paired t-test approach using the differences calculated from the nk cycles and treating these
as independent
Method 2 A mixed effects model for the difference, in which a common random effect is assumed for all
cycles from the same patient. Although Chen and Chen do not state so explicitly, because the
nk differences between treatments are the basic statistics that are modelled, rather than the
2nk original values, the random effect in question is a random interaction, the main effect
already having been eliminated by differencing.
Method 3 A mixed effects model for the 2nk original values including a period effect to cover possible
differences in average response for the 2k period simple carry-over effects a random main
effect for the patient in addition to the treatment effect and a within patient error term.
Method 4 A meta-analysis approach. From our understanding of the paper by Chen and Chen[28] as
they reference using the approach of DerSimonian and Laird[38], we have assumed the
analysis approach is a random effects meta-analysis where the random effect in question is a
random interaction.
Method 5 A fifth simple method, a summary measures approach[40], could be added to those above, and
that is to reduce all measurements on the patients to a single contrast of the difference B-A.
Thus, compared to the t-test, the unit of analysis becomes the patient rather than the cycle,
there being n estimates of the treatment effect rather than nk. We shall also consider this
alternative in due course below.
doi:10.1371/journal.pone.0167167.t001
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GenStat1 uses for analysis of variance and reflects John Nelder’s approach to linear models
[41]. ANOVA models are built up from two fundamental components: the block structure,
which reflects known variation in the experimental material and which has been reflected in
the design and the treatment structure, which reflects the nature of the treatments applied to
the experimental units.
In the work of Chen and Chen the assumption was of independent randomisation in cycles.
This means that, there are 2k possible random allocations that may be applied to any patient,
so for the design in k = 3 cycles any patient may receive one of 8 sequences and for k = 4 cycles
one of 16. However, an equal number of each treatment per patient could be attained by a
more complete randomisation, one in which (2k)!/(k!k!) possible sequences could be used.
This yields 20 such sequences for k = 3 and 70 such sequences for k = 4.
The restriction of forcing each treatment to appear once in each cycle makes sense if the
purpose is to achieve some sort of local control for individual trend effects for each patient.
This would be the case if one expected random fluctuations over time. It needs a variance term
to cover this in any simulation. This in turn implies that the block structure is cycles nested
within patients or Patient/Cycle to use the Wilkinson and Rogers (W&R) notation[42] and this
together with a simple treatment structure of ‘Treatment’ in turn yields the valid analysis of
variance decomposition according to randomisation theory using the general balance
approach of Nelder[33, 34].
This can be easily implemented in GenStat1, which in advance of having any actual mea-
surements for the design, will propose the skeleton analysis of variance. For a design with 12
patients and 3 cycles the result is shown in Table 2
(Note that Patient/Cycle is equivalent to Patient + Patient.Cycle, that is to say the main
effect of patient plus the interaction of patient and cycle, and that the statistical package R
would use Patient:Cycle to represent the latter term, whereas SAS1 would use PatientCycle.)
The important point in this is that the 1 degree of freedom for treatment has to be com-
pared to the 35 degrees of freedom associated with the cycles. In such a design there are 12 x
3 = 36 cycles and this analysis is equivalent to the matched pairs method of Chen and Chen,
since this would analyse 36 differences and remove one degree of freedom from the variance
estimate for the overall mean. The general situation is shown in the second column of Table 3.
Note there is a disturbing feature of the analysis and that is that residual degrees of freedom
exceed the number of patients. In general, for such a design, we will have nk-1 residual degrees
of freedom but only n-1 patients so that for k> 1, this will always be the case. Senn and Hil-
debrand[43] drew attention to this as a general feature of cross-over trials with more than two
Table 2. Degrees of freedom for a design with the block structure Patient/Cycle. The second column
gives the degrees of freedom for treatment structure Treatment and the third with Treatment. Patient added.
The case of 12 patients and 3 cycles is illustrated.
Analysis
Without interaction With interaction
Source of variation df df
Patient stratum 11 11
Patient.Cycle stratum 24 24
Patient.Cycle.*Units* stratum
Treatment 1 1
Patient.Treatment NA 11
Residual 35 24
Total 71 71
doi:10.1371/journal.pone.0167167.t002
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periods and, in fact, explicitly considered the case where two patients were repeatedly treated
in many periods. They pointed out that the phenomenon of treatment-by-patient interaction
might cause problems for inferences made from models using only one error term. (See [44]
for a more recent recognition of this.)
If treatment-by-patient interaction is added to the treatment structure for the above analy-
sis, then GenStat1 delivers the decomposition shown in the third column of Table 2.
There are 11 degrees of freedom for interaction, the number arising as the product of 12–1
for patients and 2–1 for treatments. The analysis of variance will now remove these 11 degrees
of freedom for interaction from the residual, An exactly analogous phenomenon arises in fixed
effects meta-analysis where the trial-by-treatment interaction is removed from the overall esti-
mate of variability because trial by trial the variance estimate is only local [39]. Applying the
same philosophy here, and treating each of the 12 patients as a ‘trial’, we can see how this hap-
pens. We have 3 differences for each patient. If we estimate the variance for each patient, each
such estimate has 2 degrees of freedom and there being 12 patents we end up with 24 in total.
The general case corresponding to this is given by the third column of Table 3, which con-
siders a design with n patients in k cycles with an interaction fitted.
Having the treatment-by-patient interaction as fixed could be questioned. It might be fine
for the limited purpose of establishing the average effect in the patients actually studied but in
stating our uncertainty about patients in general it might seem to be more appropriate to treat
the interaction as random. This can be done by imagining that each patient has some modifi-
cation to the overall average treatment effect that is permanent for that patient but assigned at
random. The natural extension of the matched pairs approach for dealing with this is then
Method 2 of Chen and Chen[28].
In the simulations undertaken by Chen and Chen[28] there seems to be no allowance for
treatment-by-patient interaction. Compound symmetry merely allows for two variance com-
ponents: it allows for between-patient and within-patient variation. The former, however, is a
main effect variance and not an interaction variance. It is also eliminated by subtraction due to
the formation of the within-cycle difference for both method 1 and method 2. Chen and Chen
also consider an auto-regressive process of order 1 (an AR1 process). (This allows for correla-
tion between successive observations but in such a way that given the result of the most recent
observation on a patient, those further back have no predictive value.) This does not allow for
a treatment effect that varies randomly from patient to patient and in fact it does not even
allow for a between-patient main effect, since as the interval between observations increases,
the correlation declines without limit, yet a between-patient effect would impose a limit on the
Table 3. Degrees of freedom for a design with the block structure Patient/Cycle. The second column
gives the degrees of freedom for treatment structure Treatment and the third with Treatment. Patient added.
The general case is illustrated.
Analysis
Without interaction With interaction
Source of variation df df
Patient stratum n-1 n-1
Patient.Cycle stratum n(k-1) n(k-1)
Patient.Cycle.*Units* stratum
Treatment 1 1
Patient.Treatment NA n-1
Residual nk-1 n(k-1)
Total 2nk-1 2nk-1
doi:10.1371/journal.pone.0167167.t003
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possible decline (A way to deal with this would be to assume that within patient errors alone
follow an AR1 process). The compound symmetry models for the simulation also do not allow
for variation from cycle to cycle above and beyond that which is simple within-patient varia-
tion. The AR1 models would go some way to reflecting this, albeit imperfectly.
Turning now to method 3, we see that this does not correspond to the method of randomi-
sation, which is in cycles. If there is a between-cycle variance it will not be eliminated by such a
model. The fact that the Chen and Chen simulation does not allow for a between-cycle variance
places this method in a better light than would be the case if one were allowed for. However, the
simulations of Chen and Chen allow for a common period effect. Using the W&R notation[42],
the block structure is PatientPeriod and this leads to the degrees of freedom decomposition
given in the third column of Table 4. (Note that in the W&R notation AB = A+B+A.B, where A.
B is the interaction, so that AB does not have the meaning it does in SAS1 notation.) If com-
pared with Table 2 it can be seen that the 24 degrees of freedom for cycles within patients have
been pooled with the 35 for error but 5 have been removed for the period effect. This is inappro-
priate since the extra degrees of freedom for error have been removed by design from the variabil-
ity associated with the treatment effect but not from the error term used to assess that variability.
The degrees of freedom for the general case corresponding to Table 4 are given in Table 5.
Here it is assumed that there are m periods where m is an even number and there are n patients
where n is a multiple of m. The way in which randomisation would be carried out is then
rather different to the design in cycles. One way of proceeding is as follows. First for every set
of m patients one would choose an m x m Latin square at random. Such a design will allocate
m pseudo-treatments for m patients in m periods. The rows and columns of the design chosen
Table 4. Degrees of freedom for a design with the block structure Patient*Period and the treatment
structure Treatment. The case of 12 patients and 6 periods.
Analysis
Without interaction With interaction
Source of variation df df
Patient stratum 11 11
Patient.Cycle stratum 24 24
Patient.Cycle.*Units* stratum
Treatment 1 1
Patient.Treatment NA 11
Residual 35 24
Total 71 71
doi:10.1371/journal.pone.0167167.t004
Table 5. Degrees of freedom for a design with the block structure Patient*Period and the treatment
structure Treatment. The case of n patients and m periods.
Analysis
Without interaction With interaction
Source of variation df df
Patient stratum n-1 n-1
Patient.Cycle stratum n(k-1) n(k-1)
Patient.Cycle.*Units* stratum
Treatment 1 1
Patient.Treatment NA n-1
Residual nk-1 n(k-1)
Total 2nk-1 2nk-1
doi:10.1371/journal.pone.0167167.t005
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are then permuted at random. Finally, one half of the m pseudo-treatments are labelled as
treatment A and the other half as treatment B.
In summary, therefore, the method of randomisation assumed by Chen and Chen makes
sense if
1. there is a main effect variation between patients
2. there is variation between cycles within patients.
In addition, one of the purposes of n-of-1 trials is studying individual response and this
implies
3. there is variation in such responses.
That is to say a treatment-by-patient interaction. In our opinion the parameters of the sim-
ulations of Chen and Chen do not take into account b) and c) and the results cannot be gener-
alised to these situations.
In the next section we shall start by introducing a general model that is compatible with the
randomisation scheme assumed and consider what this implies for methods of analysis.
Models for simulation and analysis[45–49]
We start by building a model that reflects a simulation that would be compatible with the
assumed block structure that corresponds to randomising within cycles within patients. The
model can be written as
Yirs ¼ li þ bir þ εirs þ Zirsti ð1Þ
where Yirs is the measured outcome for occasion s,s = 1,2 of cycle r,r = 1,2. . .k for patient i,
i = 1,2. . .n and εirs * N(0,σ2), βir * N(0,γ2), λi * N(Λ,ϕ2) and τi * N(T,ψ2) with Zirs ¼
1
2
or   1
2
depending on whether the treatment allocated to that patient, in that cycle on that
occasion, is A or B. All stochastic terms are assumed independent of each other. Here Λ is the
expected value over all patients, cycles and occasions and is a sort of grand mean and T is the
expected treatment effect over all patients. λi is a mean value for patient i. Note that the τi term
is a random treatment effect for patient i but by setting the variance ψ2 equal to 0 we can make
all such treatment effects identical. Similarly, and this is an important point we take up later,
we can choose to regard our focus of interest as being not so much T, which is the expected
value for a population of patients, as t ¼
Xn
i¼1
ti=n, the average value for the patients in this
trial. The two are only the same if ψ2 = 0 The former is a typical linear model formulation and
the latter is associated with randomisation and causal inference. An excellent discussion of the
distinction is given by Cox[50]. See also Senn[51]. For the moment, however, we stick with the
linear model formulation, which agrees with the description of a simulation below.
The way this corresponds to a simulation is as follows:
1. Set all parameter values for the simulation.
2. Choose a patient i and simulate a value λi and another value τi. These are to be retained and
used until all values for that patient have been generated.
3. Generate a value βir for cycle r of patient i. This is to be retained and used for both occasions
of that cycle of that patient’s course of treatments
4. Generate a random number Xir from U(0,1) for that cycle.
Variation in N-of-1 Trials
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5. Calculate Zir1 ¼ sign Xir   12
  
=2;Zir2 ¼   Zir1
6. Generate a value εirs for occasion s of cycle r for patient i.
7. Calculate the response as the sum of the value of λi for that patient βir for that cycle, εirs for
that occasion and the product of τi for that patient multiplied by Zirs for that occasion.
Note that if we form paired differences from Eq (1) by subtracting the value for the first
occasion in any cycle from the value for the second we obtain an equation of the form
dir ¼ Yir2   Yir1 ¼ ðZir2   Zir1Þti þ εir2   εir1 ð2Þ
Note that in Eq (2), (Zir2 − Zir1) is either equal to -1 or +1 depending on the random alloca-
tion since dir is what is sometimes referred to as a period difference. To create treatment differ-
ences (for example of the form B-A) we can divide through Eq (2) by (Zir2 − Zir1) to obtain
dir ¼ ti þ εirB   εirA ¼ Tþ di þ xir ð3Þ
where dir is the observed treatment difference for patient i in cycle r, δi is the random differ-
ence in the treatment effect for patient i to the overall expected effect T, and is a random treat-
ment-by-patient interaction with variance ψ2 and ξir is a random error term with variance 2σ2.
If Eq (3) is compared to Eq (1) of Chen and Chen (which is for their method 2) it will be found
to be the same, making due allowance for differences in notation. Thus showing, as we claimed
above, that their method 2, includes a patient-by- treatment interaction.
Provided that all patients receive the same number of cycles of treatment (which Chen and
Chen assume), their method 1, will also produce exactly the same estimate for any data-set
including, of course, any simulated one, as method 2. It thus follows that the observed varia-
tion from simulation to simulation will be identical whether their method 2 or their method 1
is used. The same is true for our proposed fifth method, the summary measures approach, and
indeed, it would be true for yet another method, which is to use the mixed model correspond-
ing to the simulation itself for estimation, in other words a model that corresponding to Eq
(1).
The summary measures approach calculates the mean difference in outcome under B
minus the mean difference in outcome under A per patient. In the literature this has been
referred to as the basic estimator approach[25] and was proposed and developed to deal with
the problem of degrees of freedom for error exceeding the number of patients. This is equiva-
lent to calculating the mean patient by patient of the within-cycle treatment difference. A
model for this statistic is thus
di: ¼
Xk
r¼1
dir
k
¼ T þ di þ
Xk
r¼1
xir
k
¼ Tþ di þ x i: ð4Þ
Each such a summary statistic has a variance of ψ2 + 2σ2/k and, since the summary statistics
are independent, the mean over the set of n patients will have variance
Var ðT^Þ ¼ c2=nþ 2s2=ðnkÞ ð5Þ
This is the true variance over all simulations of the estimate. Note that since all these meth-
ods produce the same estimate on every occasion, to the extent that we regard ourselves as esti-
mating T, the mean treatment effect for the population of patients for which those studied
could be regarded as a sample, they all have the same variance. (In fact expression (5) can be
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reached by starting with either of the models given by Eq (1) or (3).) The only question is ‘do
they estimate it correctly?’.
The answer is that all do, except the matched pairs approach, which only does so if it is the
case that ψ2 = 0. The summary measures approach does so directly by allowing the observed
variation of the independent summary statistics to produce the estimate of the variation.
Method 2 of Chen and Chen also does so correctly because it allows (implicitly) for a random
treatment-by-patient interaction, as would a method based on applying a mixed model of the
sort given by (1) to the original data. The procedure would be more laborious because it would
estimate the various components of variation and add them back again. If the only purpose is
to estimate T there is no advantage in this but for other purposes identifying components of
variation and hence estimating individual effects it is valuable[52].
By estimating the variance of the treatment effect directly from the n treatment estimates
themselves, the summary measures approach produces a sum of squares with expectation
equal to (n−1)(ψ2 + 2σ2/k) and on division by first the degrees of freedom for this estimate and
secondly the number of such statistics, n, the correct figure for the variance as given in (5) is
produced. What the matched pairs procedure does is, starting from the differences, it adds the
sums of squares for interaction to the residual sum of squares for the model fitting the interac-
tion. The former has an expectation equal
kðn   1Þðc2 þ 2s2=kÞ ¼ ðn   1Þðkc2 þ 2s2Þ
and the latter has expectation equal to
nðk   1Þ2s2
Adding the two together we have an expectation for the total of
ðn   1Þkc2 þ ðnk   1Þ2s2
Since the degrees of freedom associated with this combined sum of squares are nk−1 the
mean square has expectation equal to
n   1
nk   1
kc2 þ 2s2
If we further divide this by the number of observations, to reflect what will happen in calcu-
lating the variance of the treatment estimate that the matched pairs approach will produce we
get
n   1
nk   1
k
nk
c
2
þ
2s2
nk
¼
n   1
nk   1
c
2
n
þ
2s2
nk
ð6Þ
See also Patterson and Jones[53] for a derivation.
If (6) is compared with (5) we will see that it is only the same when either k = 1, which cor-
responds to one cycle per patient or when ψ2 = 0 and there is no treatment-by-patient interac-
tion. Otherwise, however, {(n−1)/(nk−1)}<1 and this means whereas the random patient by
treatment interaction contributes a term ψ2/n to (5) only a fraction of this is contributed to (6).
Thus (6) is an underestimate of the true variance. Hence standard errors will be too small and
confidence intervals for the treatment effect T using the matched pairs approach will not have
correct coverage (they will overstate the precision).
The same is not true if the object of the exercise is either to test the null hypothesis that the
treatment effect is zero or to provide a statement for the treatment effect in these patients. As
regards the latter it might be thought that this is of no interest. After all we have observed all
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the patients in the set of trials. However, this overlooks two facts. First, each patient could have
been randomised to 2k possible sequences of treatment but was only randomised to one. Sec-
ond each patient could have been observed longer. Due to the natural variation from occasion
to occasion captured by the term εirs either of these would have led to a different treatment
estimate for that patient.
As regards the former, if we assert the null hypothesis that there is no treatment effect then
there can also be no interaction and hence the matched pairs approach becomes a reasonable
one. At first this may seem shocking but consider the case where we only have one patient so
that n = 1. We can test the hypothesis that the treatments are identical by using that patient.
Now if we study formula (5) and formula (6) by setting n = 1 we see that they give the same
answer. The variance of the estimate for that patients becomes 2σ2/k and our estimate of that
variance will have expectation 2σ2/k and we will have used k−1 degrees of freedom to estimate
it. Each of the n patients gives us a legitimate attempt to test this theory and one approach is to
combine these estimates. We can now see the value of the structured ANOVA approach and
the relevance of Table 3. Combining the n estimates with their k−1 degrees of freedom leads to
the ANOVA test allowing for an interaction and given in column 3. This goes even beyond the
matched pairs t approach. That pools an interaction sum of squares with an error sums of
squares, whereas this isolates the latter. This is essentially the approach of fixed effects meta-
analysis, albeit using a pooled variance rather than estimating locally as is the case in meta-
analysis.
It is possible that this approach could be more powerful than the matched pairs t. However,
once a hint of efficacy has been provided by such a test, it is our recommendation that one
should go beyond it to consider other matters, including estimation of the average effect for all
patents and shrinkage estimates for future patients. This would require use of a random effects
model. The reason we mention this alternative test here is because of our work on developing
methods for rare diseases for which techniques for obtaining hints of efficacy using limited
resources may be particularly valuable.
As stated earlier details as to exactly which method of meta-analysis Chen and Chen[28]
used as their method 4 are not provided. From their formula (3) it would seem that they are
proposing a locally standardised effect size such as was used by Glass in his original meta-anal-
ysis paper. This is usually employed when combining effects from trial to trial with different
outcome measures and it would not be an obvious choice for n-of-1 trials. More usual would
be to stick with the original un-standardised scale. In that case if the estimates from each
patient are weighted equally and if the variance is estimated from the observed variation of
those estimates from patient to patient, this is nothing less than the summary measures
approach.
Note that the model we have introduced in Eq (1) is the one that corresponds to the rando-
misation scheme assumed by Chen and Chen[28]. Of their two approaches for analysis, both
the paired t-test and the mixed model using within cycle differences will produce correct sig-
nificance tests and the latter will also produce confidence intervals with correct coverage in the
presence of an interaction. As already discussed, a meta-analytic approach could also work but
this depends on how it is applied. Approach number three is rather different. This allows for a
common period effect as opposed to randomisation within cycles, which would allow for local
effects. The block structure as we have already implied is PatientsPeriods. We have already
criticised the AR1 structure assumed. There are two remaining problems, however. One is that
no random treatment-by-patient effect is allowed for, yet the existence of such effects is one of
the possible motivations for n-of-1 trials. The other is that the simple carry-over model used
assumes that carry-over from A into B is the same as from A into A etc. As has been pointed
out by Fleiss[54, 55] and Senn[56], this is not very realistic. In our opinion it is best not to
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include a carry-over term in the model but to make sure that the periods of observation for
patients are long enough for the effects of previous treatments to have disappeared.
However, a mixed model can be adapted to apply to the case of a crossed structure. Eq (1) is
then modified to look like this
Yij ¼ li þ pj þ εij þ Zijti ð7Þ
Here j = 1  2k is an indicator for the period in which the patient is treated. For example,
rather than randomising each patient to receive A or B in k = 3 cycles the patients could have
been more completely randomised to 6 periods, perhaps using a system of Latin squares as
outlined above. (In that case the number of patients recruited will be a multiple of 6.) Each
period is given a period effect πj but these are assumed to be the same for any patient. The ran-
dom within-patient term is now εij. This is a possible mixed effects model that could apply to
this alternative randomisation scheme.
Trivially, if (7) is assumed to be the data structure, then estimation using model (7) will be
appropriate. A simple alternative is to use the basic estimator approach of Senn[25]. This con-
structs a summary measure for each patient but estimates the variation of these not across the
design as a whole but first separately within each sequence. In this way the period effect, which
has been eliminated from the treatment estimate by the balanced design, is also eliminated
from the variance estimate. The reader is referred to Cross-over Trials in Clinical Research[25]
for more details.
One particular advantage, however, of using mixed models, whether of the form repre-
sented by (1) or of the form represented by (7) (depending on the design employed) is that
they permit estimation of the random effect variance, ψ2 This can then be used to produce so-
called shrinkage estimates for future patients.
Suppose that we have established the values of T, the average treatment effect and ψ2 the
variation of the treatment effect from patient to patient reasonably well on the basis of a series
of n-of-1 trials. These can then be used to improve the estimate for a future patient, i. Suppose
that this estimate is t^ i and has been established based on observing the patient for k cycles. Its
variance is then 2σ2/k By regarding T as a prior mean and ψ2 as a prior variance we can use the
method of empirical Bayes to produce an improved estimator t^i This weights ‘prior’ mean
and statistic by their respective precisions, that is to say the reciprocal of the variances.
We thus calculate
t^i ¼
1
c2
Tþ k
2s2
t^ i
1
c2
þ k
2s2
¼
2s2Tþ kc2t^ i
2s2 þ kc2
ð8Þ
The variance of this estimate can be calculated using the standard formula posterior
precision = prior precision + data precision (see for example, Miller and Miller [57]) and then
that the posterior variance is the reciprocal of the posterior precision. We thus calculate
1
1=c2 þ k=ð2s2Þ
¼
2s2c
2
2s2 þ kc2
ð9Þ
If (8) and (9) are studied it can be shown that if k = 0, which corresponds to having no data
on the current patient, then we simply use the overall mean T and the variance of our predic-
tion on the true effect for the patient is ψ2. On the other hand, if either k or ψ2/σ2 is very large
our estimate is close to t^ i and has variance close to 2σ
2/k In general, however, a weighted aver-
age ensues and the variance given by (9) is less than 2σ2/k.
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Note that these formulae are approximate and treat the parameters of the ‘prior distribu-
tion’ as known. This is clearly not quite right. For example, the variance of the prediction, T,
for a new patient for whom there are no data is assumed to be ψ2, representing the variance of
the individual treatment effect from the true average over all patients. However, the prediction
has to be issued using T^ and this as an estimate of T has a variance as given by (5) so that the
variance of the prediction will be
c
2
þ c
2
=nþ 2s2=ðnkÞ ð10Þ
A further problem is the well-known one that affects all REML estimates; the nuisance
parameters (in this instance ψ2,σ2) are not known[58]. Provided that the number of patients
on which this ‘prior distribution’ is calculated is not very few, the approximations can never-
theless prove valuable. One of us (AA) is working on an improvement to estimation of the var-
iance using the parametric bootstrap and this will form the basis of a further publication.
A good discussion is given by Cox and Solomon[59] pp55-56.
Simulation
In this section we present the results of simulations to illustrate theoretical points made above.
Unless stated otherwise, the model used for simulation is that given by Eq (1), although for
some analyses this is unnecessarily complicated. For example, where the analysis reduces to
within cycle differences, the parameter settings for pure cycle effects and hence also patient
effects are irrelevant. Also, we shall mainly be examining variances and for this purpose aver-
age treatment effects are also irrelevant. In describing the simulation settings and the figures
that accompany them we shall limit ourselves to mentioning those parameter settings that are
relevant to make the point. We shall also assume a balanced case in which all patients have
received both treatments in three cycles
Fig 1 shows true and estimated variances of the treatment estimate for the matched pairs
approach plotted against the variance ψ2 for the random treatment-by-patient interaction and
this has been increased from a value of 0 to 1 in steps of 0.1. The within-cycle variance σ2 has
been set to 1. One thousand trials have been simulated for each value of ψ2 The upper solid
line is the theoretical true variance as given by formula (5) and the pluses are the correspond-
ing values calculated as the variance of the 1000 estimates resulting from the simulation at
each value of ψ2. The lower dashed line is the estimated variance using formula (6) and the cir-
cles are the corresponding values calculated as the means of the 1000 estimated variances of
the estimate at each value of ψ2. It can be seen that simulation and theory agree.
The important feature is that as the random variance for the treatment-by-patient interaction
increases, the degree by which the estimated variance for the matched pairs t underestimates the
true variance increases. Only for the value of ψ2 = 0 do the two agree. As we have already dis-
cussed, this justifies using the matched pairs approach as a test of the strict null hypothesis that
both treatments are identical. However, if the treatments are not identical then any element of
personal response to treatment will lead to incorrect claimed coverage of confidence intervals.
Fig 2. plots the same true variance using Eq (5) as a solid line but now plots the simulated
estimated variances for the summary measures approach (diamond). Again each point repre-
sents the result of 1000 runs. It can now be seen that both of these approaches produce esti-
mated variances that are equivalent to the true one.
An example
In this section we present a simulated example to illustrate the use of various approaches. We
assume a series of n-of-1 trials in asthma for which two bronchodilators, A and B are given in
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a single dose with each period of treatment well separated by washout. We suppose that forced
expiratory volume in one second (FEV1) has been measure in mL 12 hours after treatments
and that 12 patients have been treated in three cycles each. That is to say the total number of
periods in which patients have been treated is 6. The simulated data are shown in Table 6
below. These data are also available in Excel format as S1 Table in the supplementary informa-
tion. Six of the values (two for patient 11 and four for patient 12) have been underlined and
placed in italics. First all the data will be analysed since this gives a balanced case. Second,
these six values will then be removed to illustrate the analysis in an unbalanced case.
Analysis of the balanced case using a linear model in which effects for Patient, Cycle within
Patient, Treatment-by-Patient in addition to Treatment are fitted produces an estimate of the
residual variance of 11842 ml2. This is a within-patient variance pooled across all patients and
not just calculated independently for each. The mean (naïve) treatment estimates can then be
calculated for each patient. For any given patient these are based upon k = 3 pairs and so multi-
plying the variance of 11842 ml2 by 2/k gives the estimated variance of 2/3 × 11842 ml2 =
7895ml2 and hence a standard error of
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
7985ml2
p
¼ 88:9ml The results are given in Table 7
where the number of cycles k (3 in every case) is given in column 2, the per patient naïve treat-
ment estimate in column 3 and the standard errors in column 4. Since the pooled within
patient variance is used to calculate the standard error and the number of observations is iden-
tically 3 for every patient, the standard error is identical for every patient.
For the unbalanced case the number of cycles per patient are given in column 5. These are
three as before for patients 1 to 10, for whom the estimates are identical but two for patient 11,
for whom the estimate is now 254.5 ml and one for patient 12, for whom the estimate is now
132.0. To estimate standard errors we need to obtain the residual variance from the linear
model as before but using the reduced data now available to us. Doing this we now obtain a
Fig 1. Comparison of true and estimated variances for the matched pairs approach (see text for explanation).
doi:10.1371/journal.pone.0167167.g001
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slightly higher figure of 12446 ml2. This has to be first multiplied by two and then divided by
three for patients 1 to 10 by two for patient 11 and by one for patient 12. The square root then
gives us the values in column 7.
These estimates and standard errors can be put into a conventional meta-analysis routine.
The fixed effects analysis will be appropriate if a test of the point null hypothesis that A is iden-
tical to B for every patient is undertaken and the random effects analysis if the patients are
instead treated as a random sample from some wider population and it is desired either to pro-
duce an estimate of the mean effect for this population, with associated confidence interval, or
it is desired to produce ‘shrunk’ improved estimates for the patients treated. Particularly con-
venient for this latter purpose is the metafor package in R of Viechtbauer[60]. In SAS1 the
macros developed by Senn et al may be used[61] (although the latter only produces the esti-
mates and not their standard errors).
If a fixed effects analysis is carried out for the balanced and the unbalanced cases repre-
sented in Table 7, the estimates (standard errors) for the overall results are 188.7(25.6) and
194.5 (27.5) respectively. The corresponding random effects meta-analysis results using the
DerSimonian & Laird approach are 188.7(28.4) and 194.5(29.6). All these analyses are clearly
significant. In this case there is no difference between fixed and random effect estimates (this
is inevitable for the balance case but not for the unbalanced one) but the standard errors are
somewhat higher for the random effects meta-analysis.
If the metafor package is used the rma function may be used to carry out the meta-analysis
and the blup function to produce shrunk estimates (BLUPs) and their standard errors. The
rma function gives various options for the random effects approach and we have used the
REML approach to produce the values in Table 8.
If Table 7 is studied it can be seen that the standard errors are very much smaller than is the
case for the naïve estimate. One should be a little cautious at taking these at face value since
Fig 2. Comparison of estimated variances for the summary measures approach and the mixed model with the true variance.
doi:10.1371/journal.pone.0167167.g002
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Table 6. Simulated data from a trial in asthma. The data are for 12 patients treated in 3 cycles. The data are arranged in columns by treatment given. For
each patient the first row represents the period in which the treatment was given and the second the result in ml of FEV1. Values in italics and underlined are
those which are removed to create an unbalanced set.
Treatment
Patient A B A B A B
1 1 2 3 4 6 5
2394 2686 2515 2675 2583 2802
2 2 1 3 4 6 5
2746 2726 2592 2867 2743 2742
3 1 2 3 4 6 5
2668 2560 2542 2584 2491 2737
4 1 2 3 4 6 5
2397 2696 2411 2895 2499 2760
5 2 1 3 4 5 6
3179 3221 2952 3096 2600 3192
6 1 2 4 3 5 6
2643 2496 2759 2847 2651 2860
7 1 2 3 4 5 6
2678 2843 2492 2763 2801 2890
8 2 1 3 4 5 6
2887 2862 2875 3083 2689 2967
9 2 1 3 4 6 5
2490 2841 2648 3044 2688 2914
10 2 1 3 4 6 5
2268 2576 2413 2493 2344 2699
11 2 1 4 3 6 5
2617 2923 2629 2832 2732 2866
—- —-
12 1 2 4 3 5 6
2627 2759 2712 2698 2572 2826
—- —- —- —-
doi:10.1371/journal.pone.0167167.t006
Table 7. Naïve per patient treatment estimates and estimated standard errors for the 12 patients whose data are given in Table 6. The columns
headed k give the number of observations per patient. See text for explanation.
Balanced Unbalanced
Patient K Per patient estimates Standard error k Per patient estimates Standarderror
1 3 223.7 88.9 3 223.7 91.1
2 3 84.7 88.9 3 84.7 91.1
3 3 60.0 88.9 3 60.0 91.1
4 3 348.0 88.9 3 348.0 91.1
5 3 259.3 88.9 3 259.3 91.1
6 3 50.0 88.9 3 50.0 91.1
7 3 175.0 88.9 3 175.0 91.1
8 3 153.7 88.9 3 153.7 91.1
9 3 324.3 88.9 3 324.3 91.1
10 3 247.7 88.9 3 247.7 91.1
11 3 214.3 88.9 2 254.5 111.6
12 3 124.0 88.9 1 132.0 157.8
doi:10.1371/journal.pone.0167167.t007
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they are based on approximations. How one could do better would lead us into further compli-
cations that we do not pursue here but will reserve for a further more technical paper. Never-
theless, most of the reduction compared to the standard errors given in Table 7 is genuine and
reflects the fact that in estimating treatment effects for a given patient we are able not only to
use values from that patient but values from others. Since the variance of treatment by patient
interaction is small in this example this bring about a considerable reduction.
The second point is that the estimates have been strongly shrunk towards the mean. This is
most easily seen by plotting the shrunk estimate against the naïve estimate as in Fig 3. To save
space we reproduce the unbalanced case only as this is the more interesting one.
It is noticeable that for the 10 patients for whom three cycles of measurement are available
the shrunk estimates, whilst much closer to the mean than the line of equality, all lie on a
straight line. However, the estimates for patients 11 and 12 are subject to stronger shrinkage,
since they are based on fewer measurements and thus are even closer to the overall mean.
The third point is that the standard errors for patients 11 and 12 for the unbalanced case
are higher than for the other 10. This reflects the fact that less information is available for
them. Nevertheless, most of the information available for any patient in this example is given
by the overall mean and this is reflected in the fact that the standard errors for patients 11 and
12 in the unbalanced case are only slightly higher than they are for the other 10.
Discussion
We have shown that where the randomisation has been carried out in cycles, then for the pur-
pose of testing the strict null hypothesis that two treatments are identical, the matched-pairs
approach proposed by Chen and Chen is valid. This is because under the null hypothesis that
the treatments are identical it makes no difference which treatment any patient gets and hence
the treatment-by-patient interaction is zero by hypothesis.
A further justification might be that even if one does not believe in the possibility of strict
point null being true and one wishes to avoid what has been called a type III error, choosing
the worse of two treatments, the fact that empirical evidence shows that large random effects
are generally small where the average difference between treatments are small, justifies one in
acting as if the random effects variance was zero at the dividing point of zero difference
between the two treatments.
Table 8. Shrunk estimates and standard errors for a meta-analysis of the balanced case and unbalanced cases of Table 7 using the metafor
package.
Balanced Unbalanced
Patient Estimate SE Estimate SE
1 195.1 44.5 200.1 46.7
2 169.7 44.5 173.7 46.7
3 165.1 44.5 169.0 46.7
4 217.9 44.5 223.6 46.7
5 201.7 44.5 206.8 46.7
6 163.3 44.5 167.1 46.7
7 186.2 44.5 190.8 46.7
8 182.3 44.5 186.8 46.7
9 213.6 44.5 219.1 46.7
10 199.5 44.5 204.6 46.7
11 193.4 44.5 202.6 48.7
12 176.9 44.5 190.0 50.9
doi:10.1371/journal.pone.0167167.t008
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However, as soon as estimation is the object then one has to allow for the possibility of val-
ues that are in theory well away from zero. Thus for the purpose of calculating confidence
intervals it may be wise to allow for a random patient by treatment interaction. In fact, even
for the purpose of testing the strict null it may be worth allowing for an interaction as in the
third column of Table 3. An analogy can be given with the common two sample t-test compar-
ing two means, each based on n values. Under the null hypothesis the values in two samples
have the same mean. Thus the most efficient estimate of the common variance σ2 is based on
pooling all the values from both samples together, producing a sample variance with 2n-1
degrees of freedom. This would yield a valid test. The problem is that as the means start to dif-
fer, the variance estimate will start to increase and power will be affected. It is thus better to
remove the one degree of freedom for the treatment estimate from the variance estimate and
to estimate the variance separately within each treatment group to produce an overall estimate
with 2n-2 degrees of freedom.
Returning to the case of analysing n-of-1 trials, the most powerful approach may be to
remove the interaction from the estimate of the variance and test the null hypothesis using n
(k-1) degrees of freedom. (There is an analogy to fixed effects meta-analysis here.) We make
this recommendation with some hesitation. It may be useful for rare diseases where informa-
tion is hard to get. However, for purposes other than hypothesis testing it cannot be recom-
mended. For the purpose of producing confidence intervals for the mean treatment effect a
simple valid analysis may be based on the summary measures approach. However, if it is
desired to produce shrunk estimates, then either a mixed model approach such as given by our
equations above or as produced by many statistical packages should be used.
Fig 3. Shrunk and naïve estimates for 12 patients in the unbalanced case. The solid diagonal line is a line of equality. It can be seen that the estimates for
individual patients are strongly shrunk and the dotted line gives the line of shrinkage for patients 1 to 10 who all have the same amount of information. The
value for patient 11 is shrunk more strongly than for patients 1–10 because data from one cycle are missing. For patient 12 data from two cycles are missing
and shrinkage is even stronger.
doi:10.1371/journal.pone.0167167.g003
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A further advantage to mixed models is that for the unbalanced case they are more efficient
than the summary measures approach. If some patients have been studied in fewer cycles than
others, then the summary measures approach has the disadvantage that estimates that are less
precise will be given the same weight as those that are more so. Optimal weighting requires
simultaneous estimation of the treatment-by-patient variance and the within cycle variance
and this is what the mixed model case achieves. Even more complicated is where cycles are
incomplete so that only one treatment is given within a cycle and not two. This requires esti-
mation of three components of variation.
We note that implementation of a mixed modelling approach may be difficult for many
researchers. There are a number of complications that can arise and issues that need to be con-
sidered and we have decided in interests of space not to cover these in detail here but reserve
them for a more technical exposition. A simple solution that will be easily available to many
researchers is to use the summary measures approach we have illustrated here in connection
with a meta-analysis package. The only difference from standard meta-analysis is that the vari-
ance of each estimate must be computed from a globally estimated variance rather than one
using the local information only.
When the article was under peer review the referees rightly pointed to some limitations
with what we have presented, which we feel are important to highlight here in the discussion.
The random effect model we have used to reflect possible differences in response to treat-
ment is a smooth Normal mixture. That is to say that the differences from patient to patient
from the average treatment effect are assumed to have a Normal distribution with expectation
zero and unknown variance to be estimated. It is, of course, possible to imagine quite different
models, for example, one in which there are a finite number of groups, each having a different
response. Such a finite-mixture approach has occasionally been advocated in meta-analysis
[62] and might be considered for n-of-1 trials.
We have proposed that identification of components of variance may be achieved through
designs involving randomisation as a keystone of the approach. A possible alternative might be
to rely on repeated measures within given treatment periods as being a means of identifying
within-patient random variation and hence random treatment-by-patient interaction. Such an
approach does require strong assumptions and is very much model-dependent. Nevertheless,
this general approach has been used with success in the so-called ‘population pharmacokinet-
ics’ field starting with the pioneering work of Lewis Sheiner and others[63] in the 1970s and
might be considered in those cases where repeated randomisation is difficult.
The methods we have outlined are appropriate when the patients can be regarded as being
exchangeable in advance of experimentation, that is to say that there is nothing apart from the
results gained under treatment for a particular patient (and, of course, the average results we
have from others) that can help us guide treatment for him or her. This is not the case if we
can find covariates that are predictive of general response. Note that the main effect of patients
is confounded with demographic covariates, so that adding covariates to the model brings
nothing additional in this respect. However, this is not true of treatment-by-patient interac-
tion, so using covariates might help identify the degree of response. This is promising in prin-
ciple but it is beyond the scope of this paper.
Finally, we have considered continuous outcomes only and for random effect models used
Normal-Normal mixtures. Other outcomes can be encountered in the n-of-1 setting and more
widely, of course, in the case of cross-over trials. For example, Makubate and Senn[64] used
Normal-logit mixtures for cross-over trials in infertility, some of which had repeated treatment
periods. For count data, such as, for example, seizures in epilepsy or exacerbations in pulmo-
nary disease, gamma-Poisson mixtures might be envisaged[65],
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Conclusion and Recommendations
Our recommendations are as follows.
For balanced n-of-1 designs randomised in cycles, a valid and powerful test of the strict null
hypothesis that the treatments are identical may be performed using an analysis of variance
with Patient/Cycle as the block structure and fitting a treatment-by-patient interaction.
For the purpose of producing confidence intervals and for the purpose of predicting the
effects for future patients a random treatment-by-patient interaction should be allowed for
and this is most easily done using a mixed model.
As an alternative to the design that randomises treatments within cycles in patients it may
be useful to base designs on Latin squares balancing the distribution of treatments across peri-
ods and patients. Suitable analysis involves fitting patient effects as random, period effects as
fixed and treatment-by-patient interactions as random.
A simple implementation of our general approach is by calculating summary measures for
each patient and associated standard errors (with the assumption of homoscedasticity across
patients) and using these as input to a meta-analysis. A fixed effects approach will provide a
valid test of the strict null hypothesis of equality and a random effects approach will enable
shrunk estimates to be produced.
We do not recommend attempting to adjust for carry-over but instead recommend using
washout periods of adequate length. It should be noted that such periods do not have to be
ones in which no treatment is given. The strategy of an active washout can be used[25],
whereby patients can be switched immediately from one treatment to another (if safe to do so)
but measurement starts once the effect of the previous treatment has disappeared and steady-
state has been reached.
Our final point concerns reporting. A series of n-of-1 trials forms a complex data-set that
needs to be reported in full and frank detail and a recent review by Li et al[66] of 112 studies
involving 2,278 patients in total found that reporting was often poor. The recently created
CONSORT extension for reporting N-of-1 trials (CENT)[67] statement would, if followed, do
much to improve this and we recommend that authors use it when reporting trials.
Supporting Information
S1 Table. Data for the example in Excel format. Patient (1–12) is the patient number. Cycle
(1–3) is the cycle within patient. Pair labels the 36 pairs of data by patient (first number) and
cycle (second number). Period (1–6) is the period within patient. Treatment (A or B) is the
treatment given. FEV_1 is the outcome for forced expiratory volume in one second in mL.
Missing is an indicator (1 = present, 2 = missing).
(XLS)
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